[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preclinical-alzheimer39s-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preclinical-alzheimer39s-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100589583","tms-for-cognitive-decline-in-aging-and-preclinical-ad-100589583",false,"NCT06956300","TMS for Cognitive Decline in Aging and Preclinical AD","Grit Against Cognitive Decline in Aging and Preclinical Alzheimer's Disease","Inclusion Criteria:\n\n1. Between the ages of 40-99\n2. Native English speakers\n3. Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points\n4. Cognitively normal older adults and individuals with preclinical Alzheimer's disease will be included.\n\nExclusion Criteria:\n\n1. History of head trauma involving loss of consciousness or alteration in consciousness\n2. Another major neurologic or psychiatric condition\n3. Known presence of a structural brain lesion (e.g. tumor, cortical infarct)\n4. Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body\n5. Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed\n6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.\n7. Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging\n8. History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).\n9. Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.\n10. Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.",true,"ALL","40 Years","99 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical Alzheimer's disease.\n\nThis study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls cognition. Changes resulting from this stimulation will be measured with behavioral tests, as well as by taking brain images with Magnetic Resonance Imaging (MRI).\n\nParticipants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.",[28,29,30,31],"Prodromal Alzheimer's Disease","Preclinical Alzheimer's Disease","Healthy Aging","Cognitive Decline",[33],"Transcranial Magnetic Stimulation","RECRUITING","2026-02-18",{"date":37,"type":38},"2026-02-20","ACTUAL",{"date":40,"type":38},"2025-04-07",{"date":42,"type":22},"2029-08-31",{"name":44,"class":45},"Massachusetts General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100603881","phase-1-duvax-a-phase-1-alzheimers-vaccine-study-targeting-amyloid-beta-and-tau-100603881","NCT07142278","DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau","A Phase 1 Study of the Safety and Tolerability of DUVAX, a Dual-Target Alzheimer's Vaccine (Amyloid-Beta and Tau), in Healthy Volunteers","DU-PRISM","Inclusion Criteria:\n\n* Healthy males and non-pregnant, non-lactating females, 40-65 years old\n* BMI between 18.0 and 32.0 kg\u002Fm²\n* Medically healthy with no significant abnormalities in medical history, exam, labs, ECG, or MRI\n* Signed informed consent\n* Women of childbearing potential: negative pregnancy test and use of effective contraception\n* Men: vasectomized or agree to use condoms \u002F not donate sperm during the study period\n\nExclusion Criteria:\n\n* Clinically significant medical or psychiatric illness that may affect safety or study results\n* MRI abnormalities (e.g., infarcts, microbleeds, ARIA-E) or contraindications to MRI\n* Significant lab abnormalities (e.g., liver, kidney, hematology) or positive HIV\u002FHBV\u002FHCV tests\n* Uncontrolled blood pressure, abnormal heart rate, or prolonged QTc interval\n* Recent serious illness, surgery, or investigational drug use within 30 days\n* Prior amyloid-beta or tau immunotherapy within 1 year\n* Use of immunosuppressive agents or chronic anticoagulants\n* History of severe vaccine reactions, autoimmune disease, or significant allergies","65 Years",{"count":57,"type":22},24,[59],"PHASE1","This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.",[62,63,29],"Alzheimer Disease","Alzheimer Disease (AD)",[65,66,67],"Asymptomatic Alzheimer Disease","Preclinical Alzheimer's disease","Alzheimer's disease","NOT_YET_RECRUITING","2025-10-20",{"date":71,"type":38},"2025-10-22",{"date":73,"type":22},"2025-11-01",{"date":75,"type":22},"2027-07-31",{"name":77,"class":78},"Nuravax, Inc.","INDUSTRY"]